19:24 , May 6, 2019 |  BC Innovations  |  Distillery Therapeutics

AGTR1 inhibitor nanoconjugate boosts chemo, immunotherapies in cancers

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer; breast cancer Mouse studies suggest a nanoconjugate based on the generic ATGR1 inhibitor valsartan could enhanced the efficacy of chemotherapies and checkpoint inhibitors in pancreatic and metastatic breast cancers....
05:31 , May 2, 2019 |  BC Extra  |  Company News

AstraZeneca adds oncolytic virus option through Transgene deal

AstraZeneca is taking another look at oncolytic viruses through an option deal with French biotech Transgene. On Thursday, the partners said AstraZeneca plc (LSE:AZN; NYSE:AZN) would receive an exclusive option to co-develop and commercialize five...
17:10 , Apr 23, 2019 |  BC Innovations  |  Distillery Therapeutics

SLC27A2 inhibition for lymphoma, lung, colorectal and cervical cancers

DISEASE CATEGORY: Cancer INDICATION: Lung cancer; T cell lymphoma; colorectal cancer; cervical cancer Mouse studies suggest inhibiting SLC27A2 could help treat T cell lymphoma and lung, colorectal and cervical cancers. In mouse models of T...
23:41 , Apr 19, 2019 |  BioCentury  |  Product Development

Companies poised to take Chinese checkpoints global

At least three companies are well positioned to answer FDA Oncology chief Richard Pazdur’s call to bring Chinese PD-1/PD-L1 inhibitors to the U.S. to compete on price. Two Chinese drugmakers and one U.S. company globally...
00:42 , Apr 19, 2019 |  BC Week In Review  |  Clinical News

BMS reports detailed survival data for failed Opdivo maintenance trial in SCLC

Bristol-Myers said Opdivo nivolumab plus Yervoy ipilimumab as maintenance therapy of extensive-stage disease small cell lung cancer following first-line platinum-based chemotherapy led to a median overall survival of 9.2 months vs. 9.6 months for placebo...
20:04 , Apr 18, 2019 |  BC Innovations  |  Translation in Brief

Agenus scales the AI ALPS

Agenus is using its artificial intelligence, machine learning platform to match cancer patients with the best monotherapy or combination therapy it has, and to uncover mechanisms of resistance to develop new therapies using non-responder data....
13:59 , Apr 9, 2019 |  BC Extra  |  Company News

BeiGene, BioAtla in deal for conditionally activated CTLA-4 inhibitor

BioAtla granted BeiGene a license to BA3071 (CAB-CTLA-4), a conditionally activated inhibitor of CTLA-4, that the partners will develop jointly to treat cancer. The companies plan to test the mAb as monotherapy and in combination...
23:56 , Apr 4, 2019 |  BC Week In Review  |  Clinical News

Jounce reports detailed data backing tumor-agnostic approach

Jounce reported detailed PFS and OS data at AACR for vopratelimab (JTX-2011) that support a tumor-agnostic approach for the ICOS agonist to select patient populations more likely to respond to the therapy. At the American...
22:39 , Mar 29, 2019 |  BioCentury  |  Finance

ORI goes oncolytic

Oncolytic virus company Cold Genesys continues to draw East Asian investors on the back of its data in bladder cancer. ORI Healthcare Fund L.P.'s Simone Song said the Hong Kong fund had been following Cold...
21:30 , Mar 11, 2019 |  BC Extra  |  Company News

Seres, AZ partner on microbiome research to treat cancer, predict response

Seres gained $1.27 (25%) to $6.38 on Monday after it announced a three-year partnership with AstraZeneca to evaluate microbiome-based approaches to improve and predict patient response to immunotherapies. Seres Therapeutics Inc. (NASDAQ:MCRB) will receive $20...